3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
6
Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Diseases
1
Uterine Cervical Diseases
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrent Uterine Corpus Sarcoma
1
Prostatic Neoplasms
1
Hypertension
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
pazopanib
×
Gynecologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled